Scholarlink

<p>The genetic landscape and interplay between Parkinson’s disease (PD) and epilepsy have yet to be discovered. Understanding the complex interplay between the genes involved in these disorders is crucial for developing therapeutic strategies. This study aimed to identify common hub genes of PD and epilepsy to identify appropriate drugs. The GSE202101, GSE32534, GSE7486, GSE7621, GSE20141, and GSE49036 datasets were utilized to obtain microarray data from patients with PD and epilepsy. The data underwent preprocessing and batch effect removal. Weighted gene co-expression network analysis (WGCNA) was used to identify hub genes. Finally, the hub genes were validated using the GSE7142 and GSE20295 datasets. Network analysis was performed on the detected genes and drugs retrieved from the DrugBank. A total of 84 microarray samples, including 26 epilepsy, 31 PD, and 27 normal samples, were analyzed. By applying a module connectivity of more than 0.8 and a clinical trait of more than 0.2, 167 hub genes were identified. Using two datasets for validation highlighted the CBS, RPS6KA5, SDC4, GNA13, PDK3, ARHGEF9, CDKN3, and SGK1 genes as potential hub genes. Using STRING and Drug Bank, associated genes and drugs were retrieved, resulting in 47 FDA-approved and 39 non-approved drugs being identified. Among the proposed drugs, magnesium supplements, memantine, felbamate, imidazole, talampanel, and radiprodil are hypothesized to modulate the pathogenicity of PD and epilepsy. Moreover, further clinical investigations are needed to validate their precise roles and therapeutic potential.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Drug repurposing for the interplay between Parkinson’s disease and epilepsy

  • 期刊论文

  • 发表日期：

    2026年8月4日

查看全文
  • Armin Ariaei,
  • Fereshteh Azedi Tehrani,
  • Arsh Ketabforoush,
  • Nooshin Ahmadirad,
  • Fereshteh Golab

摘要

The genetic landscape and interplay between Parkinson’s disease (PD) and epilepsy have yet to be discovered. Understanding the complex interplay between the genes involved in these disorders is crucial for developing therapeutic strategies. This study aimed to identify common hub genes of PD and epilepsy to identify appropriate drugs. The GSE202101, GSE32534, GSE7486, GSE7621, GSE20141, and GSE49036 datasets were utilized to obtain microarray data from patients with PD and epilepsy. The data underwent preprocessing and batch effect removal. Weighted gene co-expression network analysis (WGCNA) was used to identify hub genes. Finally, the hub genes were validated using the GSE7142 and GSE20295 datasets. Network analysis was performed on the detected genes and drugs retrieved from the DrugBank. A total of 84 microarray samples, including 26 epilepsy, 31 PD, and 27 normal samples, were analyzed. By applying a module connectivity of more than 0.8 and a clinical trait of more than 0.2, 167 hub genes were identified. Using two datasets for validation highlighted the CBS, RPS6KA5, SDC4, GNA13, PDK3, ARHGEF9, CDKN3, and SGK1 genes as potential hub genes. Using STRING and Drug Bank, associated genes and drugs were retrieved, resulting in 47 FDA-approved and 39 non-approved drugs being identified. Among the proposed drugs, magnesium supplements, memantine, felbamate, imidazole, talampanel, and radiprodil are hypothesized to modulate the pathogenicity of PD and epilepsy. Moreover, further clinical investigations are needed to validate their precise roles and therapeutic potential.